Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance-Reference-Cited by-同舟云学术

Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance

Published:2021-09-20 Issue:6 Volume:23 Page:537-548
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Barone Giuseppe,Barry Ailish,Bautista Francisco,Brichard Bénédicte,Defachelles Anne-Sophie,Herd Fiona,Manzitti Carla,Reinhardt Dirk,Rubio Pedro M.,Wieczorek Aleksandra,van Noesel Max M.^ORCID

Funder

eusa pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1007/s40272-021-00469-9.pdf

Reference20 articles.

1. Swift CC, Eklund MJ, Kraveka JM, Alazraki AL. Updates in diagnosis, management, and treatment of neuroblastoma. Radiographics. 2018;38:566–80. https://doi.org/10.1148/rg.2018170132

2. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18:719–31. https://doi.org/10.1016/S1470-2045(17)30186-9

3. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008–17. https://doi.org/10.1200/JCO.2014.59.4648

4. Whittle SB, Smith V, Dohert E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17:369–86. https://doi.org/10.1080/14737140.2017.1285230

5. Smith V, Foster J. High-risk neuroblastoma treatment review. Children. 2018;5:1–7. https://doi.org/10.3390/children5090114

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma;Cell Death & Disease;2024-06-18

2. Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects;Frontiers in Oncology;2024-05-15

3. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3;Cancer Immunology, Immunotherapy;2024-01

4. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [⁶⁴Cu]Cu-NOTA-ch14.18/CHO;Theranostics;2024

5. Experiences of parents of children receiving immunotherapy for neuroblastoma in China: a qualitative study;2023-10-30